Related Experiment Video
Updated: Aug 6, 2026

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
Beyond the guidelines: Vascular function as the central determinant and therapeutic target in hypertension
1Department of Regenerative Medicine, Division of Radiation Medical Science, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. yhigashi@hiroshima-u.ac.jp.
Insights
Hypertension is a systemic vascular disorder, not just high blood pressure. Focusing on vascular health, beyond blood pressure targets, is key to reducing cardiovascular risk and improving treatment.
Area of Science:
- Cardiovascular Medicine
- Vascular Biology
- Hypertension Research
Background:
- Traditional hypertension management focuses on brachial blood pressure, leaving residual cardiovascular risk.
- Emerging evidence highlights hypertension as a systemic vascular wall disorder involving endothelial dysfunction, oxidative stress, and inflammation.
- Vascular dysfunction actively drives hypertension initiation and progression, beyond elevated pressure alone.
Purpose of the Study:
- To propose a paradigm shift from pressure-centric to vessel-centric hypertension management.
- To review vascular phenotypes, assessment strategies, and therapeutic approaches targeting vascular restoration.
- To explore concepts like vascular age, residual risk, precision vascular medicine, and future AI integration.
Main Methods:
- Review of current scientific literature on hypertension pathophysiology and management.
- Analysis of emerging evidence on vascular dysfunction mechanisms.
- Discussion of macrovascular and microvascular assessment techniques.
Main Results:
- Hypertension involves complex interactions: endothelial nitric oxide deficiency, redox imbalance, inflammation, and mineralocorticoid receptor signaling.
- Microvascular rarefaction and arterial stiffening contribute to peripheral resistance and target organ injury.
- These processes create a self-reinforcing cycle sustaining hypertension.
Conclusions:
- Recognizing vascular dysfunction as central to hypertension refines risk stratification and therapeutic success.
- A vessel-centric approach, targeting vascular restoration alongside blood pressure reduction, represents the next frontier in cardiovascular medicine.
- Precision vascular medicine and AI integration hold promise for future hypertension management.
Abstract:
Hypertension has traditionally been defined and managed according to brachial blood pressure levels. Although this pressure-centric strategy has significantly reduced cardiovascular morbidity and mortality, substantial residual risk persists even among patients who achieve recommended blood pressure targets. Emerging evidence indicates that hypertension is fundamentally a systemic disorder of the vascular wall, in which endothelial dysfunction, oxidative stress, immune activation, microvascular remodeling, and progressive arterial stiffening not only result from elevated pressure but also actively drive its initiation and progression. Endothelial nitric oxide deficiency, redox imbalance with endothelial nitric oxide synthase uncoupling, T helper 17 cell-mediated inflammation, and mineralocorticoid receptor-dependent vascular signaling collectively promote increased vascular tone and structural remodeling. Microvascular rarefaction elevates peripheral resistance, while large-artery stiffening augments central pulsatile load and accelerates target organ injury. These interconnected processes create a self-reinforcing network that sustains hypertension beyond simple hemodynamic elevation. In this review, I propose a shift from a pressure-centric to a vessel-centric paradigm of hypertension. I describe mechanistically defined vascular phenotypes, discuss macrovascular and microvascular assessment strategies, and explore therapeutic approaches aimed at vascular restoration in addition to blood pressure reduction. I further examine the concepts of vascular age, residual risk, and precision vascular medicine, and consider future integration of artificial intelligence and vascular endpoints into clinical trials. Recognizing vascular dysfunction as a central determinant of hypertension may refine risk stratification, redefine therapeutic success, and represent the next frontier in cardiovascular medicine. Beyond Blood Pressure: Vascular Function as the Central Determinant and Therapeutic Target in Hypertension. FMD indicates flow-mediated vasodilation, RHI reactive hyperemia index, cFPWV carotid-femoral pulse wave velocity, baPWV brachial-ankle PWV, CAVI cardio ankle vascular index, Nox nitrite/nitrate, ADMA asymmeteric dimethylarginen, RAAS renin-angiotensin-aldosterone system, SGLT2 sodium-glucose cotransporter 2, NO nitric oxide.
Related Concept Videos
Hypertension and Regulation of Blood Pressure
Hypertension II: Pathophysiology
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hypertension IV: Drug Therapy and Lifestyle Modifications
Antihypertensive Drugs: Vasodilators
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
